Outcomes in Lung Cancer: 9-Year Experience From a Tertiary Cancer Center in India.

about

Changes in non-small cell lung cancer diagnosis, molecular testing and prognosis 2011-2016

P2860

Q58771084-DD4F1F74-DCF9-4D79-8F18-C8347534DD44

P2860

Outcomes in Lung Cancer: 9-Year Experience From a Tertiary Cancer Center in India.

Item

http://www.wikidata.org/entity/Q44853741

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Outcomes in Lung Cancer: 9-Year Experience From a Tertiary Cancer Center in India.

@en

Outcomes in Lung Cancer: 9-Year Experience From a Tertiary Cancer Center in India.

@nl

type

Item

label

Outcomes in Lung Cancer: 9-Year Experience From a Tertiary Cancer Center in India.

@en

Outcomes in Lung Cancer: 9-Year Experience From a Tertiary Cancer Center in India.

@nl

prefLabel

Outcomes in Lung Cancer: 9-Year Experience From a Tertiary Cancer Center in India.

@en

Outcomes in Lung Cancer: 9-Year Experience From a Tertiary Cancer Center in India.

@nl

P1476

Outcomes in Lung Cancer: 9-Year Experience From a Tertiary Cancer Center in India

@en

P2093

Aditya Navile Murali

http://www.w3.org/2001/XMLSchema#string

Arvind Krishnamurthy

http://www.w3.org/2001/XMLSchema#string

Ganesarajah Selvaluxmy

http://www.w3.org/2001/XMLSchema#string

Prasanth Ganesan

http://www.w3.org/2001/XMLSchema#string

Rajaraman Swaminathan

http://www.w3.org/2001/XMLSchema#string

Rejiv Rajendranath

http://www.w3.org/2001/XMLSchema#string

Shirley Sundersingh

http://www.w3.org/2001/XMLSchema#string

Tenali Gnana Sagar

http://www.w3.org/2001/XMLSchema#string

Trivadi S Ganesan

http://www.w3.org/2001/XMLSchema#string

P2860

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Epidermal Growth Factor Receptor Mutational Status and Brain Metastases in Non-Small-Cell Lung Cancer

Lung cancer in India.

Clinical and epidemiological study of EGFR mutations and EML4-ALK fusion genes among Indian patients with adenocarcinoma of the lung.

A year of anaplastic large cell kinase testing for lung carcinoma: pathological and technical perspectives.

Management of advanced lung cancer in resource-constrained settings: a perspective from India.

Clinico-pathological profile of lung cancer at AIIMS: a changing paradigm in India.

P304

459-468

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JGO.2016.006676

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Venkatraman Radhakrishnan

P577

2017-01-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29094084

http://www.w3.org/2001/XMLSchema#string

P932

5646892

http://www.w3.org/2001/XMLSchema#string

Outcomes in Lung Cancer: 9-Year Experience From a Tertiary Cancer Center in India.

about

P2860

P2860

Outcomes in Lung Cancer: 9-Year Experience From a Tertiary Cancer Center in India.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932